Shanghai PerHum Therapeutics is conducting a "study to evaluate the effect of chimeric antigen receptor (CAR) modified autologous T cells , CCT 303 in relapsed or refractory stage IV HER2 positive carcinoma. The dose escalation and dose expansion..
Relevance: 65.028656